Shield Therapeutics says OTCQX Best Market listing ahead of Accrufer US launch has 'great potential'
Shield Therapeutics PLC's (LON:STX), Tim Watts talks to Proactive London about their new US stock market quote on the OTCQX Best Market.
This decision is to support the upcoming launch of Accrufer in the US with the aim to increase relevance to US-based investors.
Watts explains that they will face no additional reporting requirements as a result of the American listing, therefore the additional costs will be 'minimal'.
Watts believes the drug has the potential to reach the realm of '£100mln worth of sales in the first three years and then on to 3-400mln by years five or six'.